The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

Eli Lilly and venture capital firm Andreessen Horowitz (a16z) are joining forces to create a unique new fund dubbed the Biotech Ecosystem Venture Fund, backed by $500 million of Lilly’s capital.

The biotech scene can be seen as fairly risky for new investors who want to put money to work. After all, it’s really tough ...

Eli Lilly (LLY) is in advanced talks to buy cancer-focused biotech Scorpion Therapeutics in a deal worth up to $2.5B, people close to the talks told Financial Times’ Oliver Barnes, Maria Heeter ...

Eli Lilly and Co., which cemented its place in Boston last year with the opening of a new research and development center, is now buying a cancer program from a Boston biotech. Eli Lilly and Co ...

And biotech companies that use cutting-edge technology or treat complex diseases will always be in demand. One such company is Eli Lilly (LLY), a global pharmaceutical leader that has been a ...

Eli Lilly will buy Boston biotech Scorpion Therapeutics’ PI3Kα inhibitor for upto $2.5bn in cash, with the latter splitting away to form a new entity with its remaining assets. Lilly’s bid to acquire ...

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...